Q-omics provides the consensus-scored P2RY10BP profile across patient tissues and cancer cell-line models. P2RY10BP expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, P2RY10BP is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, P2RY10BP RNA expression shows 10,135 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight KIRP, KIRC, and COAD as cancer lineages where P2RY10BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RY10BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RY10BP survival associations across molecular data types. P2RY10BP RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RY10BP RNA expression–survival associations across cancer types. High P2RY10BP expression shows unfavorable associations in KIRP, MESO, UCEC, THCA and KIRC, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for P2RY10BP RNA expression.
This table summarizes P2RY10BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for P2RY10BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RY10BP shows higher tumor expression in KIRC. The KIRC box plot shows higher P2RY10BP RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .036).
This table shows molecular features associated with P2RY10BP in patient tissues and cancer cell lines. In patient samples, P2RY10BP shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
